Despite numerous treatment advances, chronic hepatitis B virus (HBV) infection remains a largely incurable disease impacting more than 290 million people worldwide. All patients with chronic HBV ...

Precision BioSciences has reported initial outcomes from the ELIMINATE-B trial of PBGENE-HBV, a gene editing programme for treating chronic Hepatitis B patients who are HBeAg-negative. In cohort ...